Document is current
Any future updates will be listed below
-
Authors
Matikas, Alexios https://orcid.org/0000-0002-4122-9624
Kotsakis, Athanasios
Apostolaki, Stella
Politaki, Helen
Perraki, Maria
Kalbakis, Kostas
Nikolaou, Michalis
Economopoulou, Panagiota
Hatzidaki, Dora
Georgoulias, Vassilis
-
Funding
Funding for this research was provided by:
Stockholms Läns Landsting (K 2017-4577)
Cancerfonden (21 0277 JCIA 01)
- License Information
-
More Information
Article History
Received: 24 July 2021
Revised: 20 December 2021
Accepted: 6 January 2022
First Online: 10 February 2022
Competing interests
: AM: consultancy to Veracyte, CA, USA (no financial compensation); AK: speaker honoraria from Astra Zeneca, MSD, Bristol Meyers Squibb, Roche and research grants from Astra Zeneca; VG: research grants from Novartis, Astelas, Astra Zeneca, Pfizer; MN: speaker honoraria from Bristol Meyer Squibb, Roche, Pfizer; PE: speaker honoraria from Novartis, Astra Zeneca, MSD. The remaining authors declare no competing interests.
: The study was approved by the ethics committees at University Hospital of Heraklion, Crete and Metropolitan General Hospital, Athens. All patients provided written informed consent prior to obtaining samples. Patients that were treated within prospective randomised studies provided separate informed consent for participation in the clinical trial. This study was performed in accordance with the Declaration of Helsinki and its amendments.
